Evaluating prediction methods for glomerular filtration to optimise drug doses in obese and nonobese patients
David Busse, Jens Markus Borghardt, David Petroff, Alice Pevzner, Christoph Dorn, Nahed El‐Najjar, Wilhelm Huisinga, Hermann Wrigge, Philipp Simon, Charlotte Kloft
Abstract
Aims: The most suitable method for predicting the glomerular filtration rate (GFR) in obesity is currently debated. Therefore, multiple GFR/creatinine clearance prediction methods were applied to (morbidly) obese and nonobese patients ranging from moderate renal impairment to glomerular hyperfiltration and their predictions were rated based on observed fosfomycin pharmacokinetics, as this model drug is exclusively eliminated via glomerular filtration. Methods: The GFR/creatinine clearance predictions via the Chronic Kidney Disease Epidemiology Collaboration (CKD‐EPI), Modification of Diet in Renal Disease (MDRD; indexed and de‐indexed by body surface area) and creatinine clearance via the Cockcroft–Gault formula (CLCR CG ) using different body size descriptors were compared to the fosfomycin clearance (CL FOF ) from 30 surgical patients (body mass index = 20.1–52.0 kg m −2 ), receiving 8000 mg as intravenous infusion. Results: The concordance between CL FOF and creatinine clearance predictions was highest for CLCR CG employing either ideal body weight or adjusted body weight (if body mass >1.3 ideal body weight; CLCR CG_ABW‐Schwartz , concordance‐correlation coefficient [95% confidence interval] = 0.474 [0.156; 0.703], CCC) and GFR predictions via the de‐indexed MDRD equation (concordance‐correlation coefficient = 0.452 [0.137; 0.685]). The proportion of predicted GFR values within ±30% of the observed CL FOF (P 30 = 72.3–76.7%) was only marginally lower than the reported P 30 in the original CKD‐EPI and MDRD publications (P 30 = 84.1–90.0%). Conclusion: This analysis represents a successful proof‐of‐concept for evaluating GFR/creatinine clearance prediction methods: Across all body mass index classes CLCR CG_ABW‐Schwartz or the de‐indexed MDRD were most suitable for predicting creatinine clearance/GFR also in (morbidly) obese, CKD stage <3B individuals in therapeutic use. Their application is proposed in optimising doses for vital therapies in obese patients requiring monitoring of renal function (e.g. methotrexate dosing).